



Associate editor: R.M. Wadsworth

# Pyridine nucleotides and calcium signalling in arterial smooth muscle: from cell physiology to pharmacology

A. Mark Evans\*, Christopher N. Wyatt, Nicholas P. Kinnear, Jill H. Clark, Elisa A. Blanco

*Division of Biomedical Sciences, School of Biology, Bute Building, University of St. Andrews, St. Andrews, Fife KY16 9TS, UK*

## Abstract

It is generally accepted that the mobilisation of intracellular  $\text{Ca}^{2+}$  stores plays a pivotal role in the regulation of arterial smooth muscle function, paradoxically during both contraction and relaxation. However, the spatiotemporal pattern of different  $\text{Ca}^{2+}$  signals that elicit such responses may also contribute to the regulation of, for example, differential gene expression. These findings, among others, demonstrate the importance of discrete spatiotemporal  $\text{Ca}^{2+}$  signalling patterns and the mechanisms that underpin them. Of fundamental importance in this respect is the realisation that different  $\text{Ca}^{2+}$  storing organelles may be selected by the discrete or coordinated actions of multiple  $\text{Ca}^{2+}$  mobilising messengers. When considering such messengers, it is generally accepted that sarcoplasmic reticulum (SR) stores may be mobilised by the ubiquitous messenger inositol 1,4,5 trisphosphate. However, relatively little attention has been paid to the role of  $\text{Ca}^{2+}$  mobilising pyridine nucleotides in arterial smooth muscle, namely, cyclic adenosine diphosphate-ribose (cADPR) and nicotinic acid adenine dinucleotide phosphate (NAADP). This review will therefore focus on these novel mechanisms of calcium signalling and their likely therapeutic potential.

© 2005 Elsevier Inc. All rights reserved.

**Keywords:** NAADP; cADPR; ADP-ribosyl cyclase; Ryanodine receptor; Sarcoplasmic reticulum; Lysosomes; Artery; Smooth muscle

**Abbreviations:** 8-bromo-cADPR, 8-bromo-cyclic adenosine diphosphate-ribose; ACh, acetylcholine;  $\beta$ -NAD<sup>+</sup>,  $\beta$ -nicotinamide adenine dinucleotide (oxidized form);  $\beta$ -NADH,  $\beta$ -nicotinamide adenine dinucleotide (reduced form);  $\beta$ -NADP<sup>+</sup>,  $\beta$ -nicotinamide adenine dinucleotide phosphate; BK<sub>Ca</sub> channel,  $\text{Ca}^{2+}$ -activated potassium channel; cADPR, cyclic adenosine diphosphate-ribose; cAMP, cyclic adenosine monophosphate; cGDPR, cyclic guanosine diphosphate-ribose; cGMP, cyclic guanosine monophosphate; CICR,  $\text{Ca}^{2+}$ -induced  $\text{Ca}^{2+}$  release; ER, endoplasmic reticulum; ET-1, endothelin-1; FKBP, FK-506 binding proteins; HPV, hypoxic pulmonary vasoconstriction; IP<sub>3</sub>, inositol 1,4,5 trisphosphate; IP<sub>3</sub>R, inositol 1,4,5 trisphosphate receptor; mAChR, muscarinic acetylcholine receptors; NAADP, nicotinic acid adenine dinucleotide phosphate; PGF<sub>2 $\alpha$</sub> , prostaglandin F<sub>2 $\alpha$</sub> ; PKA, protein kinase A; ROS, reactive oxygen species; RyR, ryanodine receptors; SERCA, sarcoplasmic/endoplasmic reticulum  $\text{Ca}^{2+}$  ATPase; SR, sarcoplasmic reticulum; STOC, spontaneous transient outward potassium current.

## Contents

1. Introduction . . . . .	287
2. Synthesis and metabolism of cyclic adenosine diphosphate-ribose and nicotinic acid adenine dinucleotide phosphate . . . . .	288
3. Regulation of ADP-ribosyl cyclase and hydrolase activities . . . . .	289
3.1. Regulation of cyclic adenosine diphosphate-ribose synthesis and metabolism . . . . .	289
3.2. Regulation of nicotinic acid adenine dinucleotide phosphate synthesis and metabolism . . . . .	290
4. Cyclic adenosine diphosphate-ribose and $\text{Ca}^{2+}$ signalling via ryanodine receptors . . . . .	290
5. Cyclic adenosine diphosphate-ribose does not bind directly to ryanodine receptors . . . . .	291
6. The nicotinic acid adenine dinucleotide phosphate receptor . . . . .	292
7. Cyclic adenosine diphosphate-ribose-dependent $\text{Ca}^{2+}$ signalling in vascular smooth muscle . . . . .	292
7.1. $\text{Ca}^{2+}$ mobilisation by cyclic adenosine diphosphate-ribose in arterial smooth muscle . . . . .	293
8. Cyclic adenosine diphosphate-ribose and the regulation of resting arterial tone . . . . .	293
9. $\text{Ca}^{2+}$ -dependent vasodilation by cyclic adenosine diphosphate-ribose . . . . .	294

\* Corresponding author. Tel.: +44 1334 463579; fax: +44 1334 463600.

E-mail address: [ame3@st-and.ac.uk](mailto:ame3@st-and.ac.uk) (A.M. Evans).

10.	Cyclic adenosine diphosphate-ribose and vasoconstriction . . . . .	296
10.1.	Does cyclic adenosine diphosphate-ribose mediate vasoconstrictor-induced sarcoplasmic reticulum Ca <sup>2+</sup> release in arterial smooth muscle? . . . . .	296
10.2.	Cyclic adenosine diphosphate-ribose-dependent signalling is elicited in an agonist- and receptor subtype-specific manner . . . . .	296
10.3.	Does cyclic adenosine diphosphate-ribose facilitate Ca <sup>2+</sup> -induced Ca <sup>2+</sup> release in response to voltage-gated Ca <sup>2+</sup> influx? . . . . .	297
10.4.	Cyclic adenosine diphosphate-ribose-dependent vasoconstriction by oxidative stress . . . . .	297
11.	Cyclic adenosine diphosphate-ribose and hypoxic pulmonary vasoconstriction. . . . .	297
11.1.	Ca <sup>2+</sup> release from smooth muscle sarcoplasmic reticulum stores via ryanodine receptors underpins hypoxic pulmonary vasoconstriction . . . . .	298
11.2.	Adenosine diphosphate-ribosyl cyclase and cyclic adenosine diphosphate-ribose hydrolase activities are differentially distributed in pulmonary versus systemic artery smooth muscle . . . . .	298
11.3.	8-bromo-cyclic adenosine diphosphate-ribose inhibits hypoxic pulmonary vasoconstriction in the rat lung in situ . . . . .	298
11.4.	Cyclic adenosine diphosphate-ribose-independent and -dependent phases of smooth muscle sarcoplasmic reticulum Ca <sup>2+</sup> release by hypoxia . . . . .	299
11.5.	Functionally segregated sarcoplasmic reticulum stores: possible role of cyclic adenosine diphosphate-ribose-independent and -dependent phases of sarcoplasmic reticulum Ca <sup>2+</sup> release by hypoxia . . . . .	299
11.6.	8-bromo-cyclic adenosine diphosphate-ribose blocks hypoxic pulmonary vasoconstriction in an all-or-none manner . . . . .	299
12.	Ca <sup>2+</sup> signalling by nicotinic acid adenine dinucleotide phosphate and the regulation of arterial smooth muscle cell function. . . . .	300
12.1.	Self-inactivation by nicotinic acid adenine dinucleotide phosphate in arterial smooth muscle . . . . .	302
12.2.	Stimulus-specific Ca <sup>2+</sup> signalling by nicotinic acid adenine dinucleotide phosphate in arterial smooth muscle . . . . .	302
13.	Pharmacology of cyclic adenosine diphosphate-ribose and nicotinic acid adenine dinucleotide phosphate. . . . .	302
13.1.	Chemical synthesis of cyclic adenosine diphosphate-ribose agonists. . . . .	302
13.2.	Chemical synthesis of cyclic adenosine diphosphate-ribose antagonists . . . . .	303
13.3.	Chemical synthesis of nicotinic acid adenine dinucleotide phosphate agonists. . . . .	303
13.4.	Triazine dyes as nicotinic acid adenine dinucleotide phosphate agonists. . . . .	304
13.5.	Nicotinic acid adenine dinucleotide phosphate antagonists. . . . .	304
13.6.	Fluorescent cyclic adenosine diphosphate-ribose and nicotinic acid adenine dinucleotide phosphate analogues . . . . .	304
13.7.	Caged cyclic adenosine diphosphate-ribose and nicotinic acid adenine dinucleotide phosphate . . . . .	305
14.	Therapeutic potential . . . . .	305
15.	Concluding remarks. . . . .	305
	References . . . . .	306

## 1. Introduction

Consideration of the wide variety of processes regulated by changes in intracellular Ca<sup>2+</sup> concentration, from fertilisation and gene expression to muscle contraction and cell death, can leave us in no doubt of the need for a versatile Ca<sup>2+</sup> signalling system (Berridge et al., 2000). Consequently, not all stimuli that initiate a given cell response, say muscle contraction, do so by eliciting Ca<sup>2+</sup> signals with a common spatiotemporal pattern (Berridge et al., 2000). Conversely, not all stimuli that increase intracellular Ca<sup>2+</sup> concentration initiate a common cell response. Thus, Prentki et al. (1988) proposed that “Ca<sup>2+</sup> fingerprints” may be generated in an agonist-specific manner. However, the precise mechanisms that underpin stimulus-specific Ca<sup>2+</sup> signalling remain obscure.

We know that agonist specificity is determined, in part, by the release of Ca<sup>2+</sup> from intracellular stores in a manner

dependent on second messengers and their associated Ca<sup>2+</sup> release channels. During pharmaco–mechanical coupling in smooth muscle, it has long been accepted that many G-protein-coupled receptors induce the production of inositol 1,4,5 trisphosphate (IP<sub>3</sub>), which leads to the activation of one or more of the known IP<sub>3</sub>R subtypes on the sarcoplasmic reticulum (SR) and release of Ca<sup>2+</sup> from this store (Somlyo & Somlyo, 1994; Berridge et al., 2000). However, there is a growing body of evidence to support a role for Ca<sup>2+</sup> mobilising pyridine nucleotides in the regulation of intracellular Ca<sup>2+</sup> signalling in a number of cell types, including smooth muscle (Galione, 2002; Li et al., 2003). Consistent with this proposal, the enzymes for the synthesis and metabolism of nicotinic acid adenine dinucleotide phosphate (NAADP; Wilson et al., 1998; Patel et al., 2001; Yusufi et al., 2002) and cyclic adenosine diphosphate-ribose (cADPR; de Toledo et al., 1997; Wilson et al., 2001; Galione, 2002; Zhang et al., 2004) have been shown to be associated with smooth

Download English Version:

<https://daneshyari.com/en/article/9015938>

Download Persian Version:

<https://daneshyari.com/article/9015938>

[Daneshyari.com](https://daneshyari.com)